Lower response to immune checkpoint inhibitors may be caused by decreased numbers of tumor infiltrating lymphocytes; lower PD-1 expression; and lower mutational burden of ALM compared to other melanoma subtypes [17]. Here, PDCD1 is linked to melanoma.